United Kingdom· GB-APID-37833911000001103
Lamivudine 300mg / Tenofovir disoproxil 245mg tablets
A lamivudine and tenofovir disoproxil product containing lamivudine + tenofovir disoproxil, registered in United Kingdom by Cipla EU Ltd. The same ATC class is registered in 2 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Lamivudine and tenofovir disoproxil is registered in 2 of 19 countries.
Countries holding a registration under ATC J05AR12 (lamivudine and tenofovir disoproxil), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 1 of them publish a price we can compare per daily dose
Lamivudine and tenofovir disoproxil · ATC J05AR12
2 / 19 countries
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Lamivudine + Tenofovir disoproxil
- Manufacturer
- Cipla EU Ltd
- Country
- United Kingdom (GB)
- ATC code
- J05AR12
- ATC class
- Lamivudine and tenofovir disoproxil
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin08901117246959
- gtin08901117246966
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lamivudine and tenofovir disoproxil in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1dc2f009-10fc-4c22-8e84-706c872ce143 GET /v1/drugs/1dc2f009-10fc-4c22-8e84-706c872ce143?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "37833911000001103",
"desc": "Lamivudine 300mg / Tenofovir disoproxil 245mg tablets (Cipla EU Ltd)",
"form": "Oral tablet",
"vpid": "37845311000001102",
"source": "dmd",
"vtm_id": "37845411000001109",
"strength": "300 mg",
"substance": "Lamivudine + Tenofovir disoproxil",
"ingredient": "Lamivudine",
"supplier_code": "35061111000001109"
}See everything about lamivudine and tenofovir disoproxil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.